Status:
COMPLETED
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Collaborating Sponsors:
Hospital Avicenne
Conditions:
Enterobacterial Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The global spread of ESBL-producing enterobacteria (EBLSE) poses a real public health problem. The exposure of patients to antibiotic therapy leads to an increase in resistant bacterial populations wi...
Detailed Description
Among enterobacteria, the production of ESBL is the first cause of multi-resistance. The consequences of multidrug-resistant enterobacterial infections predominantly represented by ESBLs are currently...
Eligibility Criteria
Inclusion
- age\> 18
- ICU admitted patient
- rectal colonization of Enterobacteria
- accepting participation
- with medical insurance
Exclusion
- patient without bacterial colonization
- under antibiotics more than 24hours
- without medical insurance
Key Trial Info
Start Date :
July 19 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2021
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT03338738
Start Date
July 19 2018
End Date
May 28 2021
Last Update
June 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Paris Saint Joseph
Paris, Île-de-France Region, France, 75014